Gilead and Tubulis Sign $20M ADC Agreement for Solid Tumors with $30M Opt-in Fee and $415M Milestones

Dec 3, 2024, 12:54 PM

Gilead Sciences Inc. has entered into an exclusive option and license agreement with Tubulis to develop an antibody-drug conjugate (ADC) candidate targeting select solid tumors. The agreement includes an upfront payment of $20 million, a $30 million opt-in fee, and potential milestone payments totaling up to $415 million, along with mid-single to low double-digit tiered royalties. The specific target of the ADC has not been disclosed, but it is indicated that it will be a Topoisomerase I (TopoI) ADC.